GGrantIndex
← Leaderboards

Jun Luo

Johns Hopkins University

$3,173,526
Attributed
$3,914,676
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $513K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$3,914,676 · 4

By mechanism

R01$3,321,480 · 2
P50$318,936 · 1
R21$274,260 · 1

Top collaborators

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasm Of Prostate

Research focus

Malignant Neoplasm Of ProstateGenomicsBloodMutationProspectiveResistanceAbirateroneClinical ManagementPharmaceutical PreparationsResponseTumorTranscriptome SequencingAndrogen ReceptorTissuesSpecimenBlood SpecimenMolecularStandard Of CareCastration Resistant Prostate CancerLiquid BiopsyBaseFda ApprovedEvaluationClinical Trials

Grant awards (13)

Developmental Research Program$161,736
P50 · FY2025 · CA · contact PI
Genetic and genomic determinants of homologous recombination repair deficiency as treatment selection markers for lethal prostate cancer$355,850
R01 · FY2024 · CA · contact PI
Developmental Research Program$157,200
P50 · FY2024 · CA · contact PI
Genetic and genomic determinants of homologous recombination repair deficiency as treatment selection markers for lethal prostate cancer$367,087
R01 · FY2023 · CA · contact PI
Genetic and genomic determinants of homologous recombination repair deficiency as treatment selection markers for lethal prostate cancer$367,087
R01 · FY2022 · CA · contact PI
Genetic and genomic determinants of homologous recombination repair deficiency as treatment selection markers for lethal prostate cancer$374,578
R01 · FY2021 · CA · contact PI
Genetic and genomic determinants of homologous recombination repair deficiency as treatment selection markers for lethal prostate cancer$374,578
R01 · FY2020 · CA · contact PI
The aberrant androgen receptor underlies abiraterone/enzalutamide resistance$370,575
R01 · FY2018 · CA · contact PI
The aberrant androgen receptor underlies abiraterone/enzalutamide resistance$370,575
R01 · FY2017 · CA · contact PI
The aberrant androgen receptor underlies abiraterone/enzalutamide resistance$370,575
R01 · FY2016 · CA · contact PI
The aberrant androgen receptor underlies abiraterone/enzalutamide resistance$370,575
R01 · FY2015 · CA · contact PI
Premalignant Prostate Markers That Forebode Malignancy$135,710
R21 · FY2006 · CA · contact PI
Premalignant Prostate Markers That Forebode Malignancy$138,550
R21 · FY2005 · CA